ORM-10921 is an α-2c adrenergic receptor antagonist potentially for the treatment of schizophrenia. In the pharmacodynamic microdialysis study, ORM-10921 was found to increase extracellular dopamine levels in prefrontal cortex in the baseline conditions. In the behavioural tests, ORM-10921 displayed potent antidepressant and antipsychotic-like effects in the forced swimming test and prepulse-inhibition models analogueously with the previously reported results with structurally different α2C-selective AR antagonist JP-1302. References: Uys MM, Shahid M, Sallinen J, Harvey BH. The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat. Behav Pharmacol. 2017 Feb;28(1):9-18. doi: 10.1097/FBP.0000000000000261. PubMed PMID: 27749317.

纯度：≥98%

CAS：610782-82-6